(HAE) Haemonetics - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 2.976m USD | Total Return: -1.7% in 12m
Avg Turnover: 51.9M
EPS Trend: 90.9%
Qual. Beats: 0
Rev. Trend: 68.8%
Qual. Beats: 1
Warnings
Extended 1w
Tailwinds
No distinct edge detected
Haemonetics Corporation (HAE) is a Boston-based medical technology company focused on automated blood and plasma component collection, surgical blood salvage, and hemostasis management. Its portfolio includes the NexSys PCS plasmapheresis platform, the VASCADE vascular closure system, and TEG hemostasis analyzers used to guide clinical decisions in trauma and cardiovascular surgeries.
The company operates within the Health Care Supplies sector, where business models often rely on a razor-and-blade strategy, generating recurring revenue through the sale of proprietary single-use disposables required for their hardware installations. As plasma-derived therapies face increasing global demand for treating primary immunodeficiencies, HAE serves as a critical infrastructure provider for commercial collection centers.
Investors looking for deeper fundamental analysis may find ValueRay a useful tool for further due diligence. The company utilizes a multi-channel distribution strategy involving direct sales forces and independent distributors to reach hospitals and plasma collection organizations across international markets.
- U.S. plasma collection volume growth drives recurring revenue from disposable kits
- Expansion of VASCADE vascular closure systems captures interventional cardiology market share
- NexSys PCS technology adoption improves plasma yield and operational efficiency for customers
- Hemostasis management system sales depend on elective surgical procedure volume recovery
- Research and development spending on electrophysiology products impacts near-term operating margins
| Net Income: 97.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.06 > 1.0 |
| NWC/Revenue: 41.40% < 20% (prev 26.22%; Δ 15.18% < -1%) |
| CFO/TA 0.12 > 3% & CFO 293.2m > Net Income 97.3m |
| Net Debt (986.3m) to EBITDA (407.4m): 2.42 < 3 |
| Current Ratio: 2.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.2m) vs 12m ago -6.57% < -2% |
| Gross Margin: 57.34% > 18% (prev 0.55%; Δ 5.68k% > 0.5%) |
| Asset Turnover: 55.05% > 50% (prev 55.52%; Δ -0.48% > 0%) |
| Interest Coverage Ratio: 10.15 > 6 (EBITDA TTM 407.4m / Interest Expense TTM 24.8m) |
| A: 0.23 (Total Current Assets 834.9m - Total Current Liabilities 282.6m) / Total Assets 2.40b |
| B: 0.12 (Retained Earnings 279.3m / Total Assets 2.40b) |
| C: 0.10 (EBIT TTM 251.6m / Avg Total Assets 2.42b) |
| D: 0.15 (Book Value of Equity 242.2m / Total Liabilities 1.60b) |
| Altman-Z'' = 2.75 = A |
| DSRI: 1.09 (Receivables 216.9m/202.7m, Revenue 1.33b/1.36b) |
| GMI: 0.96 (GM 57.34% / 55.28%) |
| AQI: 1.04 (AQ_t 0.52 / AQ_t-1 0.50) |
| SGI: 0.98 (Revenue 1.33b / 1.36b) |
| TATA: -0.08 (NI 97.3m - CFO 293.2m) / TA 2.40b) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 66.84 with a total of 1,049,348 shares traded.
Over the past week, the price has changed by +16.69%,
over one month by +10.52%,
over three months by +7.39% and
over the past year by -1.69%.
Haemonetics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy HAE.
- StrongBuy: 3
- Buy: 5
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 81 | 21.2% |
P/E Trailing = 31.9463
P/E Forward = 11.4155
P/S = 2.1101
P/B = 3.3991
P/EG = 0.9508
Revenue TTM = 1.33b USD
EBIT TTM = 251.6m USD
EBITDA TTM = 407.4m USD
Long Term Debt = 1.22b USD (from longTermDebt, last quarter)
Short Term Debt = 5.01m USD (from shortTermDebt, last quarter)
Debt = 1.23b USD (from shortLongTermDebtTotal, last quarter) + Leases 7.20m
Net Debt = 986.3m USD (calculated: Debt 1.23b - CCE 245.4m)
Enterprise Value = 3.96b USD (2.98b + Debt 1.23b - CCE 245.4m)
Interest Coverage Ratio = 10.15 (Ebit TTM 251.6m / Interest Expense TTM 24.8m)
EV/FCF = 15.21x (Enterprise Value 3.96b / FCF TTM 260.4m)
FCF Yield = 6.57% (FCF TTM 260.4m / Enterprise Value 3.96b)
FCF Margin = 19.52% (FCF TTM 260.4m / Revenue TTM 1.33b)
Net Margin = 7.29% (Net Income TTM 97.3m / Revenue TTM 1.33b)
Gross Margin = 57.34% ((Revenue TTM 1.33b - Cost of Revenue TTM 569.1m) / Revenue TTM)
Gross Margin QoQ = 57.23% (prev 56.47%)
Tobins Q-Ratio = 1.65 (Enterprise Value 3.96b / Total Assets 2.40b)
Interest Expense / Debt = 2.01% (Interest Expense 24.8m / Debt 1.23b)
Taxrate = 24.00% (30.7m / 128.0m)
NOPAT = 191.3m (EBIT 251.6m * (1 - 24.00%))
Current Ratio = 2.95 (Total Current Assets 834.9m / Total Current Liabilities 282.6m)
Debt / Equity = 1.55 (Debt 1.23b / totalStockholderEquity, last quarter 796.3m)
Debt / EBITDA = 2.42 (Net Debt 986.3m / EBITDA 407.4m)
Debt / FCF = 3.79 (Net Debt 986.3m / FCF TTM 260.4m)
Total Stockholder Equity = 859.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.02% (Net Income 97.3m / Total Assets 2.40b)
RoE = 11.32% (Net Income TTM 97.3m / Total Stockholder Equity 859.8m)
RoCE = 12.10% (EBIT 251.6m / Capital Employed (Equity 859.8m + L.T.Debt 1.22b))
RoIC = 9.03% (NOPAT 191.3m / Invested Capital 2.12b)
WACC = 5.88% (E(2.98b)/V(4.21b) * Re(7.68%) + D(1.23b)/V(4.21b) * Rd(2.01%) * (1-Tc(0.24)))
Discount Rate = 7.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -4.64%
[DCF] Terminal Value 77.97% ; FCFF base≈213.2m ; Y1≈244.4m ; Y5≈359.8m
[DCF] Fair Price = 97.42 (EV 5.41b - Net Debt 986.3m = Equity 4.43b / Shares 45.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.95 | EPS CAGR: 11.36% | SUE: 0.21 | # QB: 0
Revenue Correlation: 68.77 | Revenue CAGR: 2.94% | SUE: 1.20 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.10 | Chg30d=-5.36% | Revisions=-38% | Analysts=11
EPS next Quarter (2026-09-30): EPS=1.28 | Chg30d=-3.68% | Revisions=-38% | Analysts=11
EPS current Year (2027-03-31): EPS=5.22 | Chg30d=-1.33% | Revisions=-43% | GrowthEPS=+5.3% | GrowthRev=+5.0%
EPS next Year (2028-03-31): EPS=5.77 | Chg30d=-2.37% | Revisions=-27% | GrowthEPS=+10.4% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: -43%